Genotypic, Phenotypic and Clinical Validation of GeneXpert in Extra-Pulmonary and Pulmonary Tuberculosis in India

Background Newer molecular diagnostics have brought paradigm shift in early diagnosis of tuberculosis [TB]. WHO recommended use of GeneXpert MTB/RIF [Xpert] for Extra-pulmonary [EP] TB; critics have since questioned its efficiency. Methods The present study was designed to assess the performance of GeneXpert in 761 extra-pulmonary and 384 pulmonary specimens from patients clinically suspected of TB and compare with Phenotypic, Genotypic and Composite reference standards [CRS]. Results Comparison of GeneXpert results to CRS, demonstrated sensitivity of 100% and 90.68%, specificity of 100% and 99.62% for pulmonary and extra-pulmonary samples. On comparison with culture, sensitivity for Rifampicin [Rif] resistance detection was 87.5% and 81.82% respectively, while specificity was 100% for both pulmonary and extra-pulmonary TB. On comparison to sequencing of rpoB gene [Rif resistance determining region, RRDR], sensitivity was respectively 93.33% and 90% while specificity was 100% in both pulmonary and extra-pulmonary TB. GeneXpert assay missed 533CCG mutation in one sputum and dual mutation [517 & 519] in one pus sample, detected by sequencing. Sequencing picked dual mutation [529, 530] in a sputum sample sensitive to Rif, demonstrating, not all RRDR mutations lead to resistance. Conclusions Current study reports observations in a patient care setting in a high burden region, from a large collection of pulmonary and extra-pulmonary samples and puts to rest questions regarding sensitivity, specificity, detection of infrequent mutations and mutations responsible for low-level Rif resistance by GeneXpert. Improvements in the assay could offer further improvement in sensitivity of detection in different patient samples; nevertheless it may be difficult to improve sensitivity of Rif resistance detection if only one gene is targeted. Assay specificity was high both for TB detection and Rif resistance detection. Despite a few misses, the assay offers major boost to early diagnosis of TB and MDR-TB, in difficult to diagnose pauci-bacillary TB.

[1]  G. Kubica,et al.  Sputum digestion and decontamination with N-acetyl-L-cysteine-sodium hydroxide for culture of mycobacteria. , 2015, The American review of respiratory disease.

[2]  Y. Pang,et al.  Comparison of Different Drug Susceptibility Test Methods To Detect Rifampin Heteroresistance in Mycobacterium tuberculosis , 2014, Antimicrobial Agents and Chemotherapy.

[3]  J. Klausner,et al.  Mixed Mycobacterium tuberculosis Complex Infections and False-Negative Results for Rifampin Resistance by GeneXpert MTB/RIF Are Associated with Poor Clinical Outcomes , 2014, Journal of Clinical Microbiology.

[4]  R. Melano,et al.  Profiling of rpoB Mutations and MICs for Rifampin and Rifabutin in Mycobacterium tuberculosis , 2014, Journal of Clinical Microbiology.

[5]  N. Dendukuri,et al.  Xpert MTB/RIF assay for the diagnosis of extrapulmonary tuberculosis: a systematic review and meta-analysis , 2014, European Respiratory Journal.

[6]  G. Bloemberg,et al.  Reply to “Described Diagnostic Inconsistencies Were Observed with an Obsolete Version of the Xpert MTB/RIF Assay and Are Unlikely To Recur in the Current Version of the Assay” , 2014, Journal of Clinical Microbiology.

[7]  D. Alland,et al.  Described Diagnostic Inconsistencies Were Observed with an Obsolete Version of the Xpert MTB/RIF Assay and Are Unlikely To Recur in the Current Version of the Assay , 2014, Journal of Clinical Microbiology.

[8]  L. Rigouts,et al.  Rifampin Resistance Missed in Automated Liquid Culture System for Mycobacterium tuberculosis Isolates with Specific rpoB Mutations , 2013, Journal of Clinical Microbiology.

[9]  L. Rigouts,et al.  Rifampin Drug Resistance Tests for Tuberculosis: Challenging the Gold Standard , 2013, Journal of Clinical Microbiology.

[10]  M. Seong,et al.  The Xpert® MTB/RIF assay evaluation in South Korea, a country with an intermediate tuberculosis burden. , 2012, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[11]  D. Alland,et al.  Rapid, High-Throughput Detection of Rifampin Resistance and Heteroresistance in Mycobacterium tuberculosis by Use of Sloppy Molecular Beacon Melting Temperature Coding , 2012, Journal of Clinical Microbiology.

[12]  L. Coltella,et al.  Clinical validation of Xpert MTB/RIF for the diagnosis of extrapulmonary tuberculosis , 2012, European Respiratory Journal.

[13]  A. Diacon,et al.  Xpert MTB/RIF Assay for Diagnosis of Pleural Tuberculosis , 2011, Journal of Clinical Microbiology.

[14]  C. Çavuşoğlu,et al.  Evaluation of the GeneXpert MTB/RIF Assay for Rapid Diagnosis of Tuberculosis and Detection of Rifampin Resistance in Pulmonary and Extrapulmonary Specimens , 2011, Journal of Clinical Microbiology.

[15]  C. Wright,et al.  Xpert MTB/RIF for Rapid Diagnosis of Tuberculous Lymphadenitis from Fine-Needle-Aspiration Biopsy Specimens , 2011, Journal of Clinical Microbiology.

[16]  D. Alland,et al.  Xpert MTB/RIF: a New Pillar in Diagnosis of Extrapulmonary Tuberculosis? , 2011, Journal of Clinical Microbiology.

[17]  Eduardo Gotuzzo,et al.  Rapid molecular detection of tuberculosis and rifampin resistance. , 2010, The New England journal of medicine.

[18]  J. Kop,et al.  Evaluation of the Analytical Performance of the Xpert MTB/RIF Assay , 2010, Journal of Clinical Microbiology.

[19]  Irene Ayakaka,et al.  Rapid Detection of Mycobacterium tuberculosis and Rifampin Resistance by Use of On-Demand, Near-Patient Technology , 2009, Journal of Clinical Microbiology.

[20]  I. Bastian,et al.  Mycobacterium tuberculosis Strains with Highly Discordant Rifampin Susceptibility Test Results , 2009, Journal of Clinical Microbiology.

[21]  R. Jou,et al.  Performance Assessment of the GenoType MTBDRplus Test and DNA Sequencing in Detection of Multidrug-Resistant Mycobacterium tuberculosis , 2009, Journal of Clinical Microbiology.

[22]  T. Thomsen,et al.  Videos in clinical medicine. Paracentesis. , 2006, The New England journal of medicine.

[23]  Nalin Rastogi,et al.  rpoB gene sequencing and spoligotyping of multidrug-resistant Mycobacterium tuberculosis isolates from India. , 2006, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

[24]  M. Salfinger,et al.  Use of Smear-Positive Samples To Assess the PCR-Based Genotype MTBDR Assay for Rapid, Direct Detection of the Mycobacterium tuberculosis Complex as Well as Its Resistance to Isoniazid and Rifampin , 2006, Journal of Clinical Microbiology.

[25]  Barun Mathema,et al.  Molecular Epidemiology of Tuberculosis: Current Insights , 2006, Clinical Microbiology Reviews.

[26]  P. V. van Helden,et al.  Reinfection and mixed infection cause changing Mycobacterium tuberculosis drug-resistance patterns. , 2005, American journal of respiratory and critical care medicine.

[27]  R. Jou,et al.  Genetic Diversity of Multidrug-Resistant Mycobacterium tuberculosis Isolates and Identification of 11 Novel rpoB Alleles in Taiwan , 2005, Journal of Clinical Microbiology.

[28]  F. Kramer,et al.  Rapid Detection of Rifampin Resistance in Mycobacterium tuberculosis Isolates from India and Mexico by a Molecular Beacon Assay , 2004, Journal of Clinical Microbiology.

[29]  P. V. van Helden,et al.  Prediction of Drug Resistance in M. tuberculosis: Molecular Mechanisms, Tools, and Applications , 2002, IUBMB life.

[30]  F. Kramer,et al.  Detection of Rifampin Resistance inMycobacterium tuberculosis in a Single Tube with Molecular Beacons , 2001, Journal of Clinical Microbiology.

[31]  H. Aramaki,et al.  Rifampicin resistance and mutation of the rpoB gene in Mycobacterium tuberculosis. , 1996, FEMS microbiology letters.

[32]  D. Snider,et al.  Multidrug-resistant Tuberculosis , 1992, Annals of Internal Medicine.

[33]  D. Soll,et al.  Occurrence and stability of insertion sequences in Mycobacterium tuberculosis complex strains: evaluation of an insertion sequence-dependent DNA polymorphism as a tool in the epidemiology of tuberculosis , 1991, Journal of clinical microbiology.

[34]  L. Heifets,et al.  Minimal inhibitory concentrations of isoniazid, rifampin, ethambutol, and streptomycin against Mycobacterium tuberculosis strains isolated before treatment of patients in Taiwan. , 1988, The American review of respiratory disease.

[35]  J. V. Gorkom Rapid Implementation of the Xpert MTB/RIF diagnostic test , 2012 .

[36]  Suhail Ahmad,et al.  Performance comparison of four methods for detecting multidrug-resistant Mycobacterium tuberculosis strains. , 2011, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[37]  A. Van Deun,et al.  Drug susceptibility testing proficiency in the network of supranational tuberculosis reference laboratories. , 2011, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[38]  J. Andrews,et al.  HIV coinfection in multidrug- and extensively drug-resistant tuberculosis results in high early mortality. , 2010, American journal of respiratory and critical care medicine.

[39]  Y. Amdekar,et al.  Multidrug resistant tuberculosis. , 1998, Indian pediatrics.